利索-全球专利检索

  1. 登录
  2. 注册

搜索结果

45 条记录 (耗时 0.049 秒)

    Structurally designed shRNAs
    31.
    发明授权
    Structurally designed shRNAs 有权
    结构设计的shRNA

    公开(公告)号：US08273871B2

    公开(公告)日：2012-09-25

    申请号：US13252784

    申请日：2011-10-04

    申请人： Gregory J. Hannon ,  Sihem Cheloufi

    发明人： Gregory J. Hannon ,  Sihem Cheloufi

    IPC分类号： C12Q1/68 ,  C12P19/34 ,  C12N15/63 ,  C07H21/02 ,  C07H21/04

    CPC分类号： C12N15/113 ,  A01K2207/05 ,  C12N15/111 ,  C12N2310/14 ,  C12N2310/141 ,  C12N2310/531 ,  C12N2320/30

    摘要： Provided is an improved design of shRNA based on structural mimics of miR-451 precursors. These miR-451 shRNA mimics are channeled through a novel small RNA biogenesis pathway, require AGO2 catalysis and are processed by Drosha but are independent of DICER processing. This miRNA pathway feeds active elements only into Ago2 because of its unique catalytic activity. These data demonstrate that this newly identified small RNA biogenesis pathway can be exploited in vivo to produce active molecules.

    摘要翻译： 提供了基于miR-451前体结构模拟的shRNA的改进设计。 这些miR-451 shRNA模拟物通过新的小RNA生物发生途径引导，需要AGO2催化，并且由Drosha处理，但是独立于DICER处理。 由于其独特的催化活性，该miRNA通路将活性成分仅供应到Ago2中。 这些数据表明，这种新鉴定的小RNA生物发生途径可以在体内被利用来产生活性分子。

    Kit for detecting the level of cyclin-dependent kinase inhibitor P16 gene expression
    34.
    发明授权
    Kit for detecting the level of cyclin-dependent kinase inhibitor P16 gene expression 失效
    用于检测细胞周期蛋白依赖性激酶抑制剂P16基因表达水平的试剂盒

    公开(公告)号：US07691632B2

    公开(公告)日：2010-04-06

    申请号：US12195135

    申请日：2008-08-20

    申请人： David H. Beach ,  Douglas J. Demetrick ,  Manuel Serrano ,  Gregory J. Hannon

    发明人： David H. Beach ,  Douglas J. Demetrick ,  Manuel Serrano ,  Gregory J. Hannon

    IPC分类号： C07K16/00

    CPC分类号： G01N33/5011 ,  C07K2319/23 ,  G01N33/574 ,  G01N2333/4736 ,  Y10S435/81

    摘要： The present invention relates to the discovery in eukaryotic cells, particularly mammalian cells, of a family of cell-cycle regulatory proteins (“CCR-proteins”). As described herein, this family of proteins includes a polypeptide having an apparent molecular weight of 16 kDa, and a polypeptide having an apparent molecular weight of approximately 15 kDa, each of which can function as an inhibitor of cell-cycle progression, and therefore ultimately of cell growth. The present invention comprises antibodies directed to such CCR-proteins. The present invention is directed to a kit for detecting the level of cyclin-dependent kinase inhibitor p16 gene expression comprising antibodies directed to a p16 protein.

    摘要翻译： 本发明涉及在真核细胞，特别是哺乳动物细胞中发现一系列细胞周期调节蛋白（“CCR-蛋白”）。 如本文所述，该蛋白质家族包括表观分子量为16kDa的多肽和表观分子量约15kDa的多肽，其各自可用作细胞周期进程的抑制剂，因此最终 的细胞生长。 本发明包括针对这种CCR-蛋白的抗体。 本发明涉及用于检测包含针对p16蛋白的抗体的细胞周期蛋白依赖性激酶抑制剂p16基因表达水平的试剂盒。

    NOVEL STRUCTURALLY DESIGNED shRNAs
    39.
    发明申请
    NOVEL STRUCTURALLY DESIGNED shRNAs 有权
    新的结构设计的shRNA

    公开(公告)号：US20130179999A1

    公开(公告)日：2013-07-11

    申请号：US13642802

    申请日：2011-04-22

    申请人： Gregory J. Hannon ,  Sihem Cheloufi

    发明人： Gregory J. Hannon ,  Sihem Cheloufi

    IPC分类号： C12N15/113

    CPC分类号： C12N15/113 ,  A01K2207/05 ,  C12N15/111 ,  C12N2310/14 ,  C12N2310/141 ,  C12N2310/531 ,  C12N2320/30

    摘要： Provided is an improved design of shRNA based on structural mimics of miR-451 precursors. These miR-451 shRNA mimics are channeled through a novel small RNA biogenesis pathway, require AGO2 catalysis and are processed by Drosha but are independent of DICER processing. This miRNA pathway feeds active elements only into Ago2 because of its unique catalytic activity. These data demonstrate that this newly identified small RNA biogenesis pathway can be exploited in vivo to produce active molecules.

    摘要翻译： 提供了基于miR-451前体结构模拟的shRNA的改进设计。 这些miR-451 shRNA模拟物通过新的小RNA生物发生途径引导，需要AGO2催化，并且由Drosha处理，但是独立于DICER处理。 由于其独特的催化活性，该miRNA通路将活性成分仅供应到Ago2中。 这些数据表明，这种新鉴定的小RNA生物发生途径可以在体内被利用来产生活性分子。